Safety of a Clozapine Trial Following Quetiapine-Induced Leukopenia: A Case Report

Author(s): Asma H. Almaghrebi *.

Journal Name: Current Drug Safety

Volume 14 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Background: The clozapine-derivative quetiapine has been shown in some cases to cause leukopenia and neutropenia.

Case Presentation: We reported on a case of a young female diagnosed with treatment-resistant schizophrenia. After failed trials of three antipsychotic medications and despite a history of quetiapineinduced leukopenia, clozapine treatment was introduced due to the severity of the patient’s symptoms, the limited effective treatment options, and a lack of guidelines on this issue.

Result: Over a ten-week period of clozapine treatment at 700 mg per day, the patient developed agranulocytosis. Her white blood cell count sharply dropped to 1.6 × 109 L, and her neutrophils decreased to 0.1 × 109 L. There had been no similar reaction to her previous medications (carbamazepine, risperidone, and haloperidol).

Conclusion: The safety of clozapine in a patient who has previously experienced leukopenia and neutropenia with quetiapine requires further investigation. Increased attention should be paid to such cases. Careful monitoring and slow titration are advisable.

Keywords: Clozapine, quetiapine, leukopenia, neutropenia, agranulocytosis, schizophrenia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [80 - 83]
Pages: 4
DOI: 10.2174/1574886313666180807094654
Price: $58

Article Metrics

PDF: 41
PRC: 1